Latest News
Gemma Biotherapeutics doses first parent in GB221 Phase 1/2 CHARISMA clinical trial
27 February 2026 - Gemma Biotherapeutics (GEMMABio), a US-based clinical-stage global genetic medicines company, announced on Thursday that it has dosed its first parent in the Phase 1/2 CHARISMA clinical trial of GB221, an investigational, next-gene...
Arna Pharma signs MOU with Slate Run Pharmaceuticals
27 February 2026 - Arna Pharma Inc, an Australia-based global pharmaceutical company, and US-based Slate Run Pharmaceuticals, announced on Thursday that they have signed an MOU to establish a scaled-up United States based specialty pharmaceutical joi...
Neurizon Therapeutics doses first participant in NUZ-001 Regimen I HEALEY ALS Platform Trial
27 February 2026 - Neurizon Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF), an Australia-based clinical-stage biotechnology company, announced on Thursday that it has dosed its first participant in Regimen I of the HEALEY ALS Platform Tria...
Circio reports up to 50-fold gene expression gain in eye for circVec-AAV platform
26 February 2026 - Biotechnology company Circio Holding ASA (OSE:CRNA) on Thursday reported new in vivo data showing that its AAV-circVec 4.0 platform achieved up to 50-fold higher gene expression in the eye versus conventional mRNA-based AAV followi...
Melodia Therapeutics reports award of US patent covering MLD-151
26 February 2026 - Melodia Therapeutics AG, a clinical-stage biotechnology company based in Switzerland, announced on Wednesday that the United States Patent and Trademark Office (USPTO) has granted a key a key patent covering a structurally novel DP...